Free Trial
→ The REAL Reason Trump is Invading Iran (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:GRI

GRI Bio Q2 2024 Earnings Report

GRI Bio logo
$2.01 0.00 (0.00%)
Closing price 04:00 PM Eastern
Extended Trading
$2.06 +0.05 (+2.24%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

GRI Bio EPS Results

Actual EPS
-$2,341.92
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GRI Bio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GRI Bio Announcement Details

Quarter
Q2 2024
Date
8/13/2024
Time
N/A
Conference Call Date
Wednesday, August 14, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

GRI Bio's Q2 2026 earnings is estimated for Thursday, August 13, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, August 12, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Slide Deck

GRI Bio's Q2 2024 Slide DeckFull Screen Slide Deck
Powered by Quartr

Earnings Documents

GRI Bio's Q2 2024 Press ReleasePress Release
(8-K)
GRI Bio's Q2 2024 Quarterly ReportQuarterly Report
(10-Q)

GRI Bio Earnings Headlines

Nano-X Imaging Maps Global Rollout for Nanox.ARC X, AI Imaging Platform
May 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30799538
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase
May 18, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/gri-bio-to-present-at-a-g-p-s-annual-healthcare-company-showcase-1036171505
I was right about SpaceX
Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel
June 3 at 1:00 AM  |  Brownstone Research (Ad)
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
May 18, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/18/3296710/0/en/gri-bio-to-present-at-a-g-p-s-annual-healthcare-company-showcase.html
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued ...
May 14, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-profile-of-gri-0621-in-idiopathic-pulmonary-fibrosis-and-highlights-continued-advancement-of-differentiated-1036155905
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
May 14, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/14/3294952/0/en/gri-bio-reports-first-quarter-2026-financial-results-new-data-reinforcing-differentiated-profile-of-gri-0621-in-idiopathic-pulmonary-fibrosis-and-highlights-continued-advancement-o.html
See More GRI Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GRI Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GRI Bio and other key companies, straight to your email.

About GRI Bio

GRI Bio (NASDAQ:GRI), a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.

View GRI Bio Profile
Earnings Tools